We are live on
!
Find out more
EU
Emory University Portfolio holdings
AUM
$267M
1-Year Est. Return
48.26%
This Fund
S&P 500
This Quarter
Est. Return
+3.18%
1 Year Est. Return
+48.26%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$102M
AUM Growth
–
Cap. Flow
+$101M
Cap. Flow
% of AUM
99.49%
Top 10 Holdings %
Top 10 Hldgs %
47.6%
Holding
42
New
42
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Berkshire Hathaway Class A
BRK.A
|
+$27M |
| 2 |
ACHN
Achillion Pharmaceuticals
ACHN
|
+$2.41M |
| 3 |
Aclaris Therapeutics
ACRS
|
+$2.31M |
| 4 |
TG Therapeutics
TGTX
|
+$2.23M |
| 5 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$2.16M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 37.19% |
| 2 | Financials | 36.35% |
| 3 | Energy | 6.89% |
| 4 | Technology | 6.32% |
| 5 | Consumer Discretionary | 4.89% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Berkshire Hathaway Class A
BRK.A
$1.06T
| $28.6M | 28.12% |
+117
| New | +$27M |
|
|
2
Aclaris Therapeutics
ACRS
$793M
| $2.46M | 2.42% |
+90,704
| New | +$2.31M |
|
3
Neurogene
NGNE
$744M
| $2.37M | 2.34% |
+7,185
| New | +$1.93M |
|
|
SMC
4
Summit Midstream
SMC
$407M
| $2.2M | 2.17% |
+5,837
| New | +$1.99M |
|
5
Acadia Pharmaceuticals
ACAD
$4.38B
| $2.19M | 2.16% |
+76,121
| New | +$2.01M |
|
|
ZGNX
6
DELISTED
Zogenix, Inc.
ZGNX
| $2.16M | 2.13% |
+177,841
| New | +$1.95M |
|
|
ALXN
7
DELISTED
Alexion Pharmaceuticals
ALXN
| $2.16M | 2.13% |
+17,657
| New | +$2.16M |
|
8
Ascendis Pharma A/S
ASND
$17.1B
| $2.12M | 2.09% |
+104,793
| New | +$2.09M |
|
9
Incyte
INCY
$23.4B
| $2.07M | 2.03% |
+20,601
| New | +$2.01M |
|
|
DBVT
10
DBV Technologies
DBVT
$870M
| $2.05M | 2.02% |
+5,826
| New | +$2.09M |
|
11
Ardelyx
ARDX
$1.28B
| $1.98M | 1.95% |
+139,357
| New | +$1.98M |
|
|
SIOX
12
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
| $1.97M | 1.94% |
+19,854
| New | +$2.09M |
|
13
BioMarin Pharmaceuticals
BMRN
$11.5B
| $1.91M | 1.88% |
+23,047
| New | +$1.98M |
|
|
GHDX
14
DELISTED
Genomic Health, Inc.
GHDX
| $1.89M | 1.86% |
+64,147
| New | +$1.96M |
|
|
ACHN
15
DELISTED
Achillion Pharmaceuticals
ACHN
| $1.88M | 1.85% |
+454,102
| New | +$2.41M |
|
16
Nektar Therapeutics
NKTR
$2.31B
| $1.87M | 1.84% |
+10,171
| New | +$2.07M |
|
17
CBRE Group
CBRE
$41.3B
| $1.79M | 1.76% |
+56,765
| New | +$1.64M |
|
18
Allison Transmission
ALSN
$9.42B
| $1.77M | 1.74% |
+52,527
| New | +$1.63M |
|
19
Bread Financial
BFH
$4.01B
| $1.77M | 1.74% |
+9,691
| New | +$1.69M |
|
|
20
TG Therapeutics
TGTX
$8.4B
| $1.76M | 1.74% |
+379,499
| New | +$2.23M |
|
21
Microsoft
MSFT
$2.93T
| $1.75M | 1.72% |
+28,152
| New | +$1.69M |
|
22
Morgan Stanley
MS
$339B
| $1.74M | 1.71% |
+41,070
| New | +$1.55M |
|
|
BHI
23
DELISTED
Baker Hughes
BHI
| $1.73M | 1.7% |
+26,634
| New | +$1.58M |
|
24
Arch Capital
ACGL
$35.4B
| $1.73M | 1.7% |
+60,117
| New | +$1.63M |
|
|
VISN
25
Vistance Networks Inc
VISN
$2.74B
| $1.73M | 1.7% |
+46,474
| New | +$1.58M |
|
Similar funds
CFG
PC
ALC
TWM
IP
SP
EAIC
STB
Emory University's Q4 2016 Portfolio in Review
Q4 2016 is the first quarter with a 13F filing on record for Emory University, which disclosed 42 positions worth $102M. Its ten largest holdings account for 48% of the portfolio.
Its largest position is Berkshire Hathaway Class A: 117 shares worth $28.6M.
By sector, the portfolio is most concentrated in Healthcare at 37% of assets, followed by Financials and Energy.
- Emory University's largest Q4 2016 buy was Berkshire Hathaway Class A: 117 shares worth $28.6M.
- Emory University's ten largest holdings make up 48% of its $102M portfolio in Q4 2016.
- Emory University disclosed 42 positions in Q4 2016, its first 13F filing on record.
Based on Emory University's 13F filing for Q4 2016, filed 13 Feb 2017.